The mOS of individuals with Stage IV LUAD who received EGFR‐TKIs combined with radiotherapy (brain metastasis, bone metastasis, or thoracic radiotherapy) was 30.7, 31.9, and 36.6 months, respectively (Figure 2A,C,E). This evidence concerns the gene EGFR and bone metastasis.